The story of daraxonrasib is the ultimate hero’s journey

A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Dear Colleagues,

Those of us who have devoted our careers to treating recalcitrant cancers know the heartbreak of walking alongside an individual facing an advanced diagnosis. We not only shoulder the clinical responsibility, but also the emotional weight that accompanies every step of that journey as each patient’s story becomes connected to our own.

We also know the pain that comes with failures in the scientific domain or when an early, promising finding fails to deliver on the promise for patient outcomes. 

What we get to experience less often is the collective, spontaneous joy that comes from a major win. I am not just referring to the chance to share a practice-changing result, but the feeling of a mutual expression of relief to the point of catharsis, and unbridled hope. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
W. Kimryn Rathmell, MD, PhD, MMHC
CEO, The James Cancer Hospital and Solove Research Institute, Director, The Ohio State University Comprehensive Cancer Center; Former director, National Cancer Institute

YOU MAY BE INTERESTED IN

The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out. 
W. Kimryn Rathmell, MD, PhD, MMHC
CEO, The James Cancer Hospital and Solove Research Institute, Director, The Ohio State University Comprehensive Cancer Center; Former director, National Cancer Institute

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login